Cochrane · systematic review · CD005128
Interventions for preventing and treating kidney disease in IgA vasculitis
Hahn, D, Hodson, EM, Craig, JC · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 2 · 28.6%Moderate 4 · 57.1%High 1 · 14.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 3 versionsPrednisone versus placebo or supportive treatment for preventing persistent kidney disease in patients with IgAV (Henoch‐ Schönlein Purpura)
Population: patients with IgAV
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Persistent kidney disease at any time after treatment Prednisone vs placebo or supportive treatment | RR 0.74 [0.42, 1.32] | 5 studies · 746 participants | Moderate Downgraded: risk of bias |
Children with any continuing kidney disease at 3 months Prednisone vs placebo or supportive treatment | RR 0.83 [0.46, 1.52] | 4 studies · 655 participants | Moderate Downgraded: risk of bias, imprecision |
Children with any continuing kidney disease at 6 months Prednisone vs placebo or supportive treatment | RR 0.51 [0.24, 1.11] | 3 studies · 379 participants | Moderate Downgraded: risk of bias, imprecision |
Children with any continuing kidney disease at 12 months Prednisone vs placebo or supportive treatment | RR 1.06 [0.38, 2.91] | 3 studies · 455 participants | Low Downgraded: risk of bias, imprecision |
Any continuing kidney disease at 3 months (study with high risk of bias excluded) Prednisone vs placebo or supportive treatment | RR 0.98 [0.7, 1.36] | 3 studies · 487 participants | High |
Any continuing kidney disease at 12 months (study with high risk of bias excluded) Prednisone vs placebo or supportive treatment | RR 1.39 [0.75, 2.59] | 2 studies · 287 participants | Moderate Downgraded: imprecision |
Number developing severe kidney disease Prednisone vs placebo or supportive treatment | RR 1.58 [0.42, 6] | 2 studies · 418 participants | Low Downgraded: imprecision |